IPHAInnate Pharma SA同业对比
Innate Pharma SA 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPHA本股 | $127M#6 | — | — | — | — | — | — | — | — | — | -27.0%#6 | — |
| FENC | $362M#4 | — | 8.5x#2 | 8.1x#2 | -6.1%#4 | -2134.2%#6 | -14.1%#2 | -22951.3%#2 | -23.1%#2 | — | 28.1%#1 | — |
| GNTA | $22M#8 | — | — | — | — | — | — | — | — | — | -62.9%#8 | — |
| GPLB | — | — | — | — | — | -0.8%#3 | — | — | — | — | — | — |
| IMCR | $1.5B#2 | — | 3.6x#1 | 3.8x#1 | 29.0%#3 | 30.5%#2 | -11.3%#1 | -8.5%#1 | -12.1%#1 | — | -8.3%#3 | — |
| IMTX | $924M#3 | — | — | — | — | — | — | — | — | — | -25.5%#5 | — |
| MEOBF | — | — | — | — | 191.4%#1 | -16.1%#4 | — | — | — | — | — | — |
| MESO | $18.5B#1 | — | — | 1076.4x#3 | 191.4%#1 | -16.1%#4 | — | — | — | — | -8.4%#4 | — |
| MOLN | $155M#5 | — | — | — | — | — | — | — | — | — | 0.8%#2 | — |
| OKYO | $73M#7 | — | — | — | — | 72.0%#1 | — | — | — | — | -46.4%#7 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-11-05。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议